Cyteir Therapeutics Inc. (CYT)
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 8:00 PM
-2.27% (1D)
| Bid | n/a |
| Market Cap | 108.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.88M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -3.247311827956989 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,006,884 |
| Avg. Volume (20D) | 167,616 |
| Open | 3.03 |
| Previous Close | 3.09 |
| Day's Range | 3.00 - 3.09 |
| 52-Week Range | 1.65 - 3.19 |
| Beta | 0.10 |
About CYT
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-185...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol CYT
Website https://cyteir.com